The phrase "assay response" is correct and usable in written English.
It can be used in contexts related to scientific or medical testing, where "assay" refers to the testing of a substance and "response" refers to the reaction or result obtained.
Example: "The assay response indicated a significant increase in enzyme activity after treatment."
Alternatives: "test result" or "analysis outcome".
Subjects with PTSD and the GG genotype tended to be more responsive to the dermal vasoconstrictor assay, and their dermal vasoconstrictor assay response correlated with higher scores on the clinician-administered PTSD scale.
The binding characteristics of the reagents used in an immunoassay determine the assay response to the analyte concentrations.
A split-plot design was employed to investigate the effects of these factors and some of their interactions on the assay response.
This assay involved the growth of cells, storage at a low temperature, activation, and exposure to a test sample, and the assay response was bioluminescence inhibition.
Association of assay response with progression-free survival (PFS) was analyzed using the Kaplan-Meier method and a Cox regression model.
Association of assay response to paclitaxel with PFS trended in multivariate analysis (hazard ratio, 1.28; 95% confidence interval, 0.84-1.95; P =.245).
Improved outcome was associated with the administration of an assay-sensitive therapy, regardless of homogeneous or heterogeneous assay responses across all of the assayed therapies.
The confirmatory assay responses are relatively close to the responses predicted.
FA assay responses were obtained with both pre-structured (adenosine) and unstructured (tyrosinamide) aptamers and with dyes of different photochemical properties (fluorescein and texas red).
Assay responses to carboplatin or paclitaxel were classified as sensitive, intermediate sensitive (IS), or resistant.
These factors are very important for facilitating binding and improving sensitivity and speed of sensor and assay responses.
